Hologic, Inc. (HOLX) Stock
Hologic, Inc.
Company profile
Hologic reported revenue of $4.10 billion for fiscal year 2025, up 1.7% from fiscal year 2024, and net income of $565.70 million. That is a net profit margin of 13.8% for fiscal year 2025. In Q1 2026 (the quarter ended December 31, 2025) revenue was $1.05 billion, up 2.5% from a year before. Its largest business segment, Diagnostics, brought in 45% of segment revenue in fiscal year 2025; United States was the largest region with 74%. In Q1 2026 it reported net income of $179.10 million, against net income of $201.00 million a year earlier. Our analysis of its filings shows revenue growing from $4.03 billion in fiscal year 2023 to $4.10 billion in fiscal year 2025, 0.9% a year on average.
Figures from company filings; latest fiscal year ended September 30, 2025.
Largest shareholders
- Vanguard Fiduciary Trust Co.11.22%
- T. Rowe Price Investment Management, Inc.10.73%
- BlackRock Advisors LLC6.64%
- Manulife Financial Corporation4.91%
- State Street Corporation4.50%
Share of the company, as of November 8, 2025
In the news
How much revenue does Hologic make?
Hologic reported $4.10 billion in revenue for fiscal year 2025, up 1.7% from $4.03 billion in fiscal year 2024. In Q1 2026 revenue was $1.05 billion.
What is Hologic's largest business segment?
Diagnostics, with $1.83 billion or 45% of segment revenue in fiscal year 2025. Next: Breast Health (36%) and GYN Surgical (17%).
Where does Hologic make most of its revenue?
United States: 74% of revenue by region in fiscal year 2025, followed by Europe (14%).
What companies are similar to Hologic?
Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include Terumo Corporation (4543.T), PharmaResearch Co., Ltd. (214450.KQ), Olympus Corporation (7733.T), Fukuda Denshi Co., Ltd. (6960.T).
Data as of .
How to cite: DataPorium, “Hologic, Inc. (HOLX)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/HOLX